Abstract:Background: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of the original Cochrane review first published in 2005. Objectives: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life. Search strategy: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. Selection criteria: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included oestrogens, with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes. Data collection and analysis: Two authors independently assessed trial quality and extracted data. Main results: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease. Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer. The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use. Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia. Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups. The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500. However, this study was not powered to detect differences between groups of younger women. Authors' conclusions: HT is not indicated for the routine management of chronic disease. We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.

[The effect of postmenopausal hormone replacement therapy on endometrial bleeding]

Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding

Risk of Stroke in Healthy Postmenopausal Women During and after Hormone Therapy: a Meta-Analysis.

Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy

[A randomized case-control study on the influence of percutaneous estradiol and progestin in cyclic combined regimen on endometrium and vaginal bleeding pattern in Chinese early postmenopausal women]

Uterine bleeding with hormone therapies in menopausal women: a systematic review

Endometrial expression of steroid receptors in postmenopausal hormone replacement therapy users: relationship to bleeding patterns

Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime

Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review

Menopausal Symptoms in Older Women and the Effects of Treatment with Hormone Therapy

Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials

Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol

Research Progress of the Risk of Tumors of Menopausal Hormone Replacement Therapy

Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study

Hormonal replacement therapy in women with a history of internal genital organ malignancy

Menopausal hormone therapy in women with benign gynaecological conditions and cancer

The Incidence and Characteristics of Uterine Bleeding During Postoperative Gnrh Agonist Treatment Combined with Estrogen-Progestogen Add-Back Therapy in Endometriosis Patients of Reproductive Age

Long term hormone therapy for perimenopausal and postmenopausal women

Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells

Hormone Replacement Therapy and Risks of Various Cancers in Postmenopausal Women with De Novo or a History of Endometriosis